Donor and Recipient CMV Serostatus and Outcome of Pediatric Allogeneic HSCT for Acute Leukemia in the Era of CMV-Preemptive Therapy
Open Access
- 1 January 2009
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 15 (1) , 54-60
- https://doi.org/10.1016/j.bbmt.2008.10.023
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- SAS and R functions to compute pseudo-values for censored data regressionComputer Methods and Programs in Biomedicine, 2008
- Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and diseaseTransplant Infectious Disease, 2008
- Modelling competing risks in cancer studiesStatistics in Medicine, 2006
- Regression Modeling of Competing Risks Data Based on Pseudovalues of the Cumulative Incidence FunctionBiometrics, 2005
- Risk factors in pediatric stem cell transplantation for leukemiaPediatric Transplantation, 2004
- Stem cell transplantation for chronic myeloid leukemia in childrenBlood, 2003
- Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortalityBone Marrow Transplantation, 2003
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988
- The Importance of Pre Bone Marrow Transplantation Serology in Determining Subsequent Cytomegalovirus Infection: An Analysis of Risk FactorsScandinavian Journal of Infectious Diseases, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958